# Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

> **NCT05209256** · PHASE2,PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 90 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Alflutinib plus chemotherapy

## Key facts

- **NCT ID:** NCT05209256
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-01
- **Final completion:** 2025-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05209256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05209256, "Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05209256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*